Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
45.25    2.75 (6.47%)
Bid:
44.50
Ask:
46.00
Spread: 1.50 (3.371%)
Market Cap: £86.82m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Management changes

8 Mar 2010 07:00

RNS Number : 2049I
Iofina PLC
08 March 2010
 



 

8 March 2010

Iofina plc

 ("Iofina" or "the Company" or "the Group")

 

MANAGEMENT CHANGE

 

 

The Board of Iofina announces that following an organisation review in the light of the broadening scope of the Company's business Lance Baller, currently Finance Director of the Group, has been appointed as CEO of the Group in place of David Schneider, with immediate effect. It is expected that a new appointment to the role of Finance Director will be made shortly.

 Also, effective immediately, Dr Tom Becker has been appointed as President of Iofina Chemical Inc.

Dr. Becker was the former vice president of Research and Development at H&S/Iofina Chemical. Iofina bought H&S Chemical in July 2009 for complete vertical integration into the iodine chemical derivatives market. Dr. Becker has conducted extensive research in both inorganic and organic halogen based chemistry. Dr. Becker has written a magnitude of published technical papers in his career. Prior to H&S Dr. Becker worked as an Oak Ridge Scholar on behalf of the US EPA and worked for various other chemical manufacturing companies. Dr. Becker earned a BS in Chemistry from Indiana University, and a PhD in Chemistry from the University of Cincinnati. He has extensive experience in scale-up of chemical processes from laboratory to pilot to full scale production and is the inventor on several chemical patents/patent applications.

Dr. Chris Fay CBE, Non Executive Chairman commented:

"We are continually looking to strengthen Iofina's management team and Board as evidenced by a number of personnel announcements. As the Company's focus now transitions from one of exploration and technology development towards production, contract negotiations and cash generation, the Board has concluded that Lance is best placed to lead the Company through this next phase of growth to drive shareholder value creation."

For further information, please contact:

Chris Fay, Non-Exec Chairman

Iofina plc

Tel: +44(0)20 3006 3135

 

Nominated Adviser:

James Harris/Angela Peace

Strand Hanson Limited

Tel: +44(0)20 7409 3494

 

Broker:

Rory Scott

Mirabaud Securities Limited

Tel: +44(0)20 7878 3360

 

Media Contact:

Klara Kaczmarek

Pelham Bell Pottinger

Tel: +44 (0)20 7337 1524

About Iofina

Iofina is involved in the exploration and production of both iodine and natural gas with complete vertical integration into the specialty chemical iodine derivatives business. It also provides third party brine stream operators with a turnkey solution to extract iodine. The presence of both iodine and natural gas has been discovered on acreages which the Company holds through its wholly owned subsidiary Iofina Natural Gas, Inc. The presence of both iodine and natural gas allows the Group to generate dual revenue streams over a single cost structure.

Iofina is traded on the London Stock Exchange's AIM Market under the ticker: IOF

www.Iofina.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUGUMCWUPUPUM
Date   Source Headline
14th May 20197:00 amRNSStatement regarding share price rise
1st May 20197:00 amRNSFinal Results
17th Apr 20197:00 amRNSQ1 2019 Market Update
1st Apr 20197:00 amRNSCompletion of Debt Restructuring
22nd Feb 20194:40 pmRNSSecond Price Monitoring Extn
22nd Feb 20194:35 pmRNSPrice Monitoring Extension
12th Feb 20197:00 amRNSDebt Restructuring
1st Feb 20194:40 pmRNSSecond Price Monitoring Extn
1st Feb 20194:35 pmRNSPrice Monitoring Extension
22nd Jan 20197:00 amRNSChange of Registered Office
17th Jan 20197:00 amRNSMarket Update
20th Nov 20184:40 pmRNSSecond Price Monitoring Extn
20th Nov 20184:35 pmRNSPrice Monitoring Extension
16th Nov 20187:00 amRNSDirector Appointment
18th Oct 20184:40 pmRNSSecond Price Monitoring Extn
18th Oct 20184:35 pmRNSPrice Monitoring Extension
10th Oct 20187:00 amRNSQ3 2018 Update
20th Sep 20187:00 amRNSInterim Results
16th Jul 20187:00 amRNSH1 2018 Update
18th Jun 20187:00 amRNSMarket update
14th Jun 20187:00 amRNSGrant of Options
13th Jun 201811:30 amRNSResult of AGM
30th Apr 20187:00 amRNSFinal Results and Notice of AGM
18th Apr 20187:00 amRNSQ1 2018 Market Update
16th Apr 20181:30 pmRNSHolding(s) in Company
11th Apr 20186:20 pmRNSHolding(s) in Company
11th Apr 20186:20 pmRNSHolding(s) in Company
20th Mar 20183:05 pmRNSHolding(s) in Company
15th Mar 20181:24 pmRNSHolding(s) in Company
14th Feb 20187:00 amRNSProduction commences at IO#7
30th Jan 20183:00 pmRNSHolding(s) in Company
15th Jan 20187:00 amRNSMarket Update
14th Dec 20177:00 amRNSMarket Update
16th Nov 20177:00 amRNSIO#7 Progress and Market Update
20th Oct 20174:40 pmRNSSecond Price Monitoring Extn
20th Oct 20174:35 pmRNSPrice Monitoring Extension
10th Oct 20177:00 amRNSQ3 2017 Market Update
22nd Sep 20177:00 amRNSInterim Results
12th Sep 20177:00 amRNSConstruction of IO#7 to Expand Iodine Production
14th Jul 20177:00 amRNSCorporate and Production Update
14th Jun 201712:15 pmRNSResult of AGM
13th Jun 201712:07 pmRNSSecond Price Monitoring Extn
13th Jun 201712:02 pmRNSPrice Monitoring Extension
8th Jun 201712:07 pmRNSSecond Price Monitoring Extn
8th Jun 201712:02 pmRNSPrice Monitoring Extension
7th Jun 201712:07 pmRNSSecond Price Monitoring Extn
7th Jun 201712:02 pmRNSPrice Monitoring Extension
6th Jun 201712:07 pmRNSSecond Price Monitoring Extn
6th Jun 201712:02 pmRNSPrice Monitoring Extension
24th May 20174:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.